Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04699838 · ClinicalTrials.gov registry record · Phase 2
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer
A Phase 2 study of Extensive-stage Small-cell Lung Cancer, sponsored by Muhammad Furqan.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT04699838 is a Phase 2 study of Extensive-stage Small-cell Lung Cancer that is actively recruiting participants, run by Muhammad Furqan. The registered enrollment target is 30 participants, below the 174-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (83% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT04699838, a Phase 2 study of Extensive-stage Small-cell Lung Cancer, is actively recruiting participants, sponsored by Muhammad Furqan.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
The primary objective of this single arm study is to estimate the progression free survival of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy followed by maintenance therapy with durvalumab and oral ceralasertib.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- DRUG Etoposide
- DRUG Durvalumab
- DRUG Ceralasertib
Study Locations (5)
Illinois
- University of Illinois Medical Center - Chicago
Indiana
- Indiana University Melvin and Bren Simon Comprehensive Cancer Center - Indianapolis
Iowa
- University of Iowa Hospitals and Clinics - Iowa City
Maryland
- University of Maryland - Baltimore
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2021-04-20 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04699838
The ClinicalTrials.gov registry entry for NCT04699838 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 174-participant average among 25 other Extensive-stage Small-cell Lung Cancer trials with a reported enrollment target (83% lower). The listed sponsor is Muhammad Furqan, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Extensive-stage Small-cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT04699838 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Illinois, Indiana, Iowa.
Frequently Asked Questions
What is clinical trial NCT04699838 about?
NCT04699838 is a clinical study titled "Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer". The primary objective of this single arm study is to estimate the progression free survival of previously-untreated patients with extensive stage small cell lung cancer. Patients will receive initial chemo-immunotherapy followed by maintenance therapy with durvalumab and oral ceralasertib.
What is the current status of trial NCT04699838?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2021-04-20. Estimated completion is 2026-11.
What conditions does trial NCT04699838 study?
This clinical trial studies the following conditions: Extensive-stage Small-cell Lung Cancer.
What interventions are being tested in trial NCT04699838?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Etoposide (DRUG), Durvalumab (DRUG), Ceralasertib (DRUG).
Who is sponsoring clinical trial NCT04699838?
This trial is sponsored by Muhammad Furqan, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04699838 being conducted?
This trial has 5 study locations across Illinois, Indiana, Iowa, Maryland, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Extensive-stage Small-cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)
RECRUITING · Phase 2
-
Study of Bevacizumab in Combination With Chemoimmunotherapy and Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases
RECRUITING · Phase 2
-
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
ACTIVE NOT RECRUITING · Phase 2
-
MGC018 in Patients With Relapsed or Refractory Extensive-Stage Small-Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
ACTIVE NOT RECRUITING · Phase 2
-
Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.